Immediately, one of many massive market movers is Atossa Therapeutics (NASDAQ:ATOS). This Seattle-based scientific stage biopharma firm has seen a big quantity of volatility this 12 months. Immediately, shares of ATOS inventory are up roughly 9% on the time of writing. Certainly, these types of strikes appear to be par for the course of late.
This oncology and infectious disease-focused biopharma play has been on a variety of wild rides this 12 months. Shares have swung wildly from beneath $1 per share in the beginning of the 12 months to round $4.50 in February, right down to $1.50 in April, and as much as almost $10 in June. Immediately, buyers should purchase shares of ATOS for round $4 per share.
Given the volatility this inventory has seen, maybe a double-digit transfer on a given day is anticipated. For many shares, it isn’t. Nonetheless, it is a firm that has a variety of catalysts the market seems to be struggling to cost in.
Let’s dive into one such catalyst developing on Oct. 7.
Upcoming Shareholder Vote Stoking Enthusiasm in ATOS Inventory
Earlier this week, Atossa delayed its shareholder vote to Oct. 7. A vote was scheduled for the Sept. 7 assembly; nonetheless, it seems the corporate didn’t have sufficient votes secured to permitted the proposal.
What the corporate is proposing is to extend its licensed shares of widespread inventory. A majority of shareholders should approve the deal, and whereas 73% of the votes counted have been in favor, not sufficient votes have been forged in favor to approve this proposal.
Basically, the corporate intends to permit for added shares to be issued to “full and/or help acquisitions, collaborations, partnerships and licensing transactions.” In different phrases, this would supply the corporate’s administration staff with the power to make the most of the corporate’s fairness for varied strategic functions. Extra flexibility is usually a great factor. Nonetheless, buyers who haven’t voted in favor (the opposite 27%) could also be cautious of the dilutive results such share issuances carry.
Whether or not a month is sufficient time for Atossa to whip up the votes it must go this proposal is up for debate. Nonetheless, immediately’s pop seems to be the results of buyers pricing in an opportunity this proposal could not undergo (once more, associated to dilution).
This can definitely be an intriguing inventory to observe from right here.
On the date of publication, Chris MacDonald didn’t have (both instantly or not directly) any positions within the securities talked about on this article. The opinions expressed on this article are these of the author, topic to the InvestorPlace.com Publishing Guidelines.
https://investorplace.com/2021/09/atos-stock-holders-should-mark-their-calendars-for-oct-7/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feedpercent3A+InvestorPlace+%28InvestorPlacepercent29 | ATOS Inventory Holders Ought to Mark Their Calendars for Oct. 7